Daix (France), New York City (New York, United States), November 24, 2025 – Publication of information relating to the stabilization activities carried out in the context of the recent public offering of Inventiva (the "Company" or "Inventiva") in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01. As announced on 18 November 2025, the underwriters have exercised in full their option (the "Un ...

Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ...

Group 1 - Centessa Pharmaceuticals plc has announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (ADSs) at a price of $21.50 per ADS, with expected gross proceeds of approximately $250 million before deductions [1] - The offering is expected to close on or about November 14, 2025, subject to customary closing conditions, and includes a 30-day option for underwriters to purchase an additional 1,744,186 ADSs [1] - The ADSs are being offered under a registration statement filed with the SEC, which became effective upon filing [3] Group 2 - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are co-lead managers [2] - The final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website [3] Group 3 - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformative medicines, particularly in the area of orexin receptor 2 (OX2R) agonist program for treating excessive daytime sleepiness and other neurological disorders [5]

Core Viewpoint - Centessa Pharmaceuticals plc has initiated an underwritten public offering of American Depositary Shares (ADSs), with all shares being offered by the company, and plans to grant underwriters a 30-day option to purchase an additional 15% of the ADSs offered [1][2]. Company Overview - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients, particularly through its orexin receptor 2 (OX2R) agonist program aimed at treating excessive daytime sleepiness, cognitive deficits, and other neurological disorders [5]. Offering Details - The ADSs are being offered under a registration statement on Form S-3 filed with the SEC on September 11, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be accessible on the SEC's website [3]. Underwriters - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are serving as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are acting as co-lead managers [2]. Contact Information - For inquiries, the company has provided contact details for Kristen K. Sheppard, SVP of Investor Relations [7].

ATHENS, Greece, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rubico Inc. (“Rubico” or the “Company”) (Nasdaq: RUBI), a global provider of shipping transportation services specializing in the ownership of vessels, today announced the pricing of its underwritten public offering of 12,315,270 units at a public offering price of $0.609 per unit. Each unit consists of one common share and one Class A warrant to purchase one common share. Each warrant will expire one (1) year from the date of issuance, will be immediately e ...

Core Viewpoint - Veru Inc. has initiated an underwritten public offering of its common stock and related warrants to fund the development of its drug enobosarm, particularly for the Phase 2b PLATEAU clinical study [1][2]. Group 1: Offering Details - The public offering includes shares of common stock, pre-funded warrants, Series A warrants, and Series B warrants, all offered by Veru [1][3]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the terms [1]. - Canaccord Genuity LLC and Oppenheimer & Co. Inc. are the joint book-running managers for this offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily support the Phase 2b PLATEAU clinical study activities for enobosarm [2]. - Additional proceeds will be allocated for working capital, existing vendor obligations, and general corporate purposes, including collaboration with potential development partners for enobosarm [2]. Group 3: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, which was filed with the SEC on March 16, 2023, and declared effective on April 14, 2023 [3]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on the SEC's website [3].

Core Points - RAPT Therapeutics, Inc. announced a public offering of 8,333,334 shares of common stock priced at $30.00 per share, with expected gross proceeds of approximately $250 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 1,250,000 shares at the public offering price [1] - The offering is expected to close on or about October 23, 2025, subject to customary closing conditions [1] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases [5] - The company utilizes proprietary expertise in immunology to create novel therapies aimed at modulating immune responses [5] Offering Details - The offering is conducted under a shelf registration statement filed with the SEC, which was declared effective on August 17, 2023 [3] - Joint bookrunning managers for the offering include Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital [2]

Core Viewpoint - Sadot Group Inc. has announced the pricing of a public offering of 103,577 shares at $5.20 per share, aiming for gross proceeds of approximately $538,600.40, which will be used for general working capital and corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at $5.20 per share, with total gross proceeds expected to be $538,600.40 before fees and expenses [1]. - The offering is set to close on October 16, 2025, pending customary closing conditions [1]. - Dawson James Securities, Inc. is acting as the sole placement agent for this offering [2]. Group 2: Regulatory Information - The securities are being offered under a shelf registration statement on Form S-3, which was filed with the SEC on August 29, 2024, and declared effective on September 19, 2024 [3]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC and available on their website [3]. Group 3: Company Overview - Sadot Group Inc. is an emerging player in the global food supply chain, focusing on innovative and sustainable supply chain solutions to address food security challenges [5]. - The company operates in key verticals including agri-commodity origination and trading for food/feed products, as well as farm operations in Southern Africa [5]. - Sadot Group is headquartered in Burleson, Texas [5].

Core Viewpoint - Spyre Therapeutics, Inc. has announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, aiming to raise approximately $275.0 million in gross proceeds before expenses [1][2]. Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing advanced treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [5]. Offering Details - The public offering is expected to close around October 15, 2025, pending customary closing conditions [2]. - The underwriters have an option to purchase an additional 2,229,729 shares at the public offering price [1]. - Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are the joint book-running managers for the offering [2]. Regulatory Information - A registration statement related to the offering has been filed with the SEC and became effective on March 7, 2025 [3]. - The offering will be conducted through a prospectus supplement and accompanying prospectus [3].

Core Viewpoint - Palisade Bio, Inc. has announced a public offering of 171,440,559 shares of its common stock at a price of $0.70 per share, aiming to raise approximately $120 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 25,714,285 shares at the public offering price [2]. - The expected closing date for the offering is around October 2, 2025, pending customary closing conditions [3]. - A registration statement related to the offering was declared effective by the SEC on September 30, 2025, with an additional statement filed on October 1, 2025 [4]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [6]. - The company aims to transform the treatment landscape through a targeted approach with its therapeutics [6].